Influenza vaccination in the elderly.

Seasonal influenza is a prevalent and serious annual illness resulting in widespread morbidity and economic disruption throughout the population; the elderly and immunocompromised are particularly vulnerable to serious sequelae and mortality. The changing demographics worldwide to an aging society have important implications for public health policy and pharmaceutical innovations. For instance, primary prevention via immunization is effective in reducing the burden of influenza illness among the elderly. However, the elderly may be insufficiently protected by vaccination due to the immunosenescence which accompanies aging. In addition, vaccine hesitancy among the younger populations increases the likelihood of circulating infectious diseases, and thus concomitant exposure. While it is clear that the development of more immunogenic vaccines is an imperative and worthy endeavor, clinical trials continue to demonstrate that the current influenza vaccine formulation remains highly effective in reducing morbidity and mortality when well matched to circulating strains.

[Outbreak of SARG in a neonatal intensive care unit].

The article provides information on an outbreak of infection with a strain of Staphylococcus aureus resistant to gentamicin (SARG) and a hyperproducer of enterotoxins A and D at a neonatal intensive care unit of the University Hospital in Hradec Králové. A retrospective investigation was carried out that provided an overview of the presence of the SARG strain in the patients, staff and hospital environment. Subsequently, strict infection precautions were implemented and the importance of rational antimicrobial therapy was emphasized.

[Treponema pallidum subspecies pallidum -- the causative agent of neurosyphilis]. / Treponema pallidum, subspecies pallidum - puvodce neurosyfilis.

Neurosyphilis is defined as infection of central nervous system by Treponema pallidum subspecies pallidum. Neurosyphilis can develop at any stage after initial infec-tion and is reflected in laboratory results. The pathogenesis of neurosyphilis is similar to that of classical form of syphilis. Individuals with persistent abnormalities in the cerebrospinal fluid are at risk of the development of clinical manifestations. Proper understanding of particular forms of neurosyphilis for differential diagnosis is important to determine potential risk of the development of progressive disease in neurology.

[Bacterial infection as a cause of infertility in humans]. / Bakteriální infekce jako prícina neplodnosti u lidí

Microorganisms which are present in the human urogenital tract may be involved in the development of inflammatory changes negatively affecting the genitals in both men and women. Pathological conditions due to inflammatory alterations may result in complete loss of fertility. Infections of the urogenital tract are responsible for 15% of all cases of infertility in couples. Negative impact on the human reproduction is mainly caused by direct damage to the genital tract mucosa by metabolic products of microorganisms or by induction of pro-inflammatory responses of the body. Another mechanism is indirect impact of microorganisms on the genital function. Moreover, the effect of bacteria on spermatogenesis and semen quality is important in men. Infections mainly caused by Chlamydia trachomatis or Neisseria gonorrhoeae represent the greatest risk in terms of permanent consequences for human reproduction. As for other sexually transmitted disorders, such as infections caused by Gardnerella vaginalis, urogenital mycoplasmas or ureaplasmas, the link between infection and infertility has been intensively researched.

[Molecular biological and epidemiological -characteristics of the varicella-zoster virus (VZV)]. / Molekulárnebiologické a epidemiologické charakteristiky viru planých nestovic (VZV).

The genetic diversity and epidemiology of VZV results from an interplay of the geographic area, climate conditions, and population factors. Studies of the genetic diversity of VZV can have direct implications for both the epidemiological and evolutionary analyses and identification of the genetic correlates of VZV pathogenicity or resistance to antiviral drugs.

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.

Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.

Genotyping of varicella-zoster virus (vzv) wild-type strains isolated in the Czech Republic.

OBJECTIVES: Monitoring of the varicella-zoster virus is becoming an important tool for analysis of the circulation of individual strains of VZV which differ not only at the genomic level, but show a variability in their clinical and epidemiological characteristics. Such data are not available on a large scale from the Czech population and could help understanding the epidemiological and evolutionary characteristics of the virus, as well as its potential for reinfection and increased pathogenesis in the population groups at higher risk for complications. The main aim of this study was detection and monitoring of wild-type or vaccine VZV strain isolates in the region of Eastern Bohemia and genotypic characterization of these isolates. MATERIAL: A total of 273 clinical samples were obtained from patients exhibiting symptoms of varicella zoster virus (VZV) infection manifested as chickenpox or herpes zoster (HZ) treated in the Faculty Hospital of Charles University, Medical School in Hradec Kralove, Czech Republic. METHODS: Characterization of individual short VZV DNA sequences was performed utilizing restriction fragment length polymorphisms (RFLPs), PCR and sequencing. Single nucleotide polymorphisms (SNP) in open reading frames (ORF) 21, 22 and 50 were used to identify individual VZV strains. RESULTS: All clinical isolates (97 from varicella, 176 from herpes zoster) were VZV positive wild-type strains. Sequencing analysis showed that 89 isolates were of the European E1 genotype, 180 were of the European E2 genotype and 2 were identified as the Mosaic M1 strain. In addition, for the first time in this region two unusual genotypes were identified, both representing a combination of E1 and M2 strain specific SNPs. CONCLUSION: Our prospective VZV genotyping study which is the first to monitor the VZV epidemiological situation in the Czech Republic using such a large set of clinical specimens, has provided valuable epidemiological data and identified two unique VZV recombinants.

An unusual case of multi-recurrent herpes zoster (Hz): a case report.

AIMS: We report a case of multi-recurrent herpes zoster in a 53-year-old Caucasian woman treated repeatedly at the Faculty Hospital Hradec Kralove, Czech Republic over the years 2009 - 2011. METHODS: Specific PCR methods targeting single nucleotide polymorphisms (SNPs) in open reading frames (ORF) 38, 54 and 62 were utilized to determine vaccine or wild type varicella-zoster (VZV) strains followed by SNPs analysis using two amplicons in ORF 22 and/or ORF 21/ORF 50. Additional genotyping in ORF 1, 6, 9 and 28 was subsequently performed due to the unusual results. RESULTS: Three sets of clinical specimens from one patient (from hospital visits 2, 3 and 4) were analyzed and the presence of an unusual wild-type strain of VZV was discovered. The VZV strain isolated from the lesions bears a combination of markers characteristic both for Mosaic 2 (M2) and European 1 (E1) wild-type VZV strains. CONCLUSION: This is the first report of atypical wild-type VZV strain circulating currently in Czech Republic.

Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes.

Phylogenetic analysis of 19 complete VZV genomic sequences resolves wild-type strains into 5 genotypes (E1, E2, J, M1, and M2). Complete sequences for M3 and M4 strains are unavailable, but targeted analyses of representative strains suggest they are stable, circulating VZV genotypes. Sequence analysis of VZV isolates identified both shared and specific markers for every genotype and validated a unified VZV genotyping strategy. Despite high genotype diversity no evidence for intra-genotypic recombination was observed. Five of seven VZV genotypes were reliably discriminated using only four single nucleotide polymorphisms (SNP) present in ORF22, and the E1 and E2 genotypes were resolved using SNP located in ORF21, ORF22 or ORF50. Sequence analysis of 342 clinical varicella and zoster specimens from 18 European countries identified the following distribution of VZV genotypes: E1, 221 (65%); E2, 87 (25%); M1, 20 (6%); M2, 3 (1%); M4, 11 (3%). No M3 or J strains were observed.

Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.

This randomized (1:1), double-blind, multicenter study, included 4,968 healthy infants to receive either the 11-valent pneumococcal protein D (PD)-conjugate study vaccine or the hepatitis A vaccine (HAV) (control) at 3, 4, 5, and 12-15 months of age. The three-dose primary course of both vaccines was co-administered with combined hexavalent DTPa-HBV-IPV/Hib vaccine. The pneumococcal PD-conjugate study vaccine did not impact the immune response of co-administered hexavalent vaccine and the control HAV vaccine induced seropositivity (antibodies >or=15 mIU/mL) in all infants. The incidence of solicited symptoms was higher with the 11-valent pneumococcal PD-conjugate study vaccine, yet similar to that induced by concomitant DTPa-HBV-IPV/Hib vaccine. Overall, the reactogenicity and safety profile of the 11-valent pneumococcal PD-conjugate vaccine when co-administered with the hexavalent DTPa-HBV-IPV/Hib vaccine, as well as the immunogenicity of the co-administered hexavalent vaccine, were consistent with previous reports for the licensed DTPa-HBV-IPV/Hib and pneumococcal conjugate vaccines.

[Experience with the PCR method in chlamydia detection.].

PURPOSE OF THE STUDY: The study was intended to summarize and evaluate the results in patients with a suspected infection by the genus Chlamydia, investigated with an in-house method of nested PCR (polymerase chain reaction). The study worked with data from patients living in eastern Bohemia, who were examined in the years 2001-2003 at the Dept. of Molecular Biology, a research laboratory shared by the Institute of Clinical Microbiology and the Institute of Clinical Biochemistry and Diagnostics. MATERIAL AND METHODS: 291 explorations were done in 2001, in 2002 already 562 and in 2003 their figure reached 760. The total number of samples received for investigation during that period was 1 613. 1 587 were actually investigated, 26 were unsuitable and could not be used. More than 70 % of all investigations were done with three types of material: urine (41.8 % of all the investigated samples), BAL (15.3 % of all the investigated samples) and whole blood (14.9 % of all the investigated samples). The investigations were carried out with the in-house nested PCR method, which uses primers from the MOMP(ompA) area of the genus Chlamydia spp. RESULTS: Total positivity was 5.67 %, in 1.26 % of the samples the resulted was considered uncertain and 93.07 % of the investigated samples were negative. In men PCR positivity was 6.11 %, in women 5.35 %. The major proportion of positive samples was from the age groups 70-79 years (11.67 %), 10-19 years (6.51 %) and 40-49 years (6.45 %). Overall positivity in smears from the urogenital system was 6.48 %, from urine 3.92 %, from BAL 10.70 % and from whole blood 5.51 %. KEYWORDS: nested PCR, Chlamydia spp., detection.

Botulism and bioterrorism: how serious is this problem?

Botulism is a potentially lethal disease caused by one of seven homologous neurotoxic proteins usually produced by the bacterium, Clostridium botulinum. This neuromuscular disorder occurs through an exquisite series of molecular events, ultimately ending with the arrest of acetylcholine release and hence, flaccid paralysis. There are three types of botulism: food, wound, and infant botulism. Most strains of the bacterium produce a potent, respiratory muscle-paralyzing neurotoxin, botulinum toxin (BTX). It can lead to death unless appropriate therapy is promptly initiated. Due to the severity and potency of BTX, its importance as a biological weapon is of major concern to public health officials. Nevertheless, BTX is also medicament.

Anthrax vaccines.

Anthrax, an uncommon disease in humans, is caused by a large bacterium, Bacillus anthracis. The risk of inhalation infection is the main indication for anthrax vaccination. Pre-exposure vaccination is provided by an acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin elements and results in protective immunity after 3 to 6 doses. Anthrax vaccine precipitated (AVP) is administered at primovaccination in 3 doses with a booster dose after 6 months. To evoke and maintain protective immunity, it is necessary to administer a booster dose once at 12 months. In Russia, live spore vaccine (STI) has been used in a two-dose schedule. Current anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever). Serious adverse reactions occur in about 1% of vaccinations. New second-generation vaccines in current research programs include recombinant live vaccines and recombinant sub-unit vaccines.

Q fever outbreak during the Czech Army deployment in Bosnia.

An epidemic of Q fever was identified among soldiers from the Czech Republic serving in the U.N. Stabilization Force in Bosnia and Herzogovina in 1997. There were 26 serologically confirmed infections, or 4.6% of those exposed. There were 14 cases of febrile illness and 12 subclinical infections. Prodromal symptoms of malaise, headache, backache, and fatigue were followed by fever > or = 39 degrees C with an intermittent course. Physical findings were unremarkable except in five cases with radiographically confirmed pneumonia. Cases were treated with doxycycline, trimethoprim-sulfamethoxazole, or ceftriaxone and supportive care. Q fever occurred at four U.N. Stabilization Force bases with the highest incidence at Dolna Ljubija (attack rate 9.4% vs. 2.3% at other locations (risk ratio = 4.0; 95% confidence interval [CI] = 2.7-5.9; p < 0.05). A sheep farm with active lambing was located 100 m from the base. Helicopter operations at a nearby landing zone may have generated infectious environmental aerosols and may have been a cause of the Q fever outbreak.

Anthrax toxin characterization.

The anthrax toxin comprises three proteins. When they work together, they can kill humans, especially after spores of the bacteria have been inhaled. One anthrax protein, called protective antigen (PA), chaperones the two other toxins into human or animal cells and shields them from the body's immune system. The second, lethal factor (LF), destroys the white blood cells that hosts send in defence. The third toxin molecule, edema factor (EF), hijacks the signaling system in the body. This disrupts the energy balance of cells and leads to them accumulating fluid and complete destroy of cells.

Prophylaxis against anthrax.

The paper presents fundamental knowledge concerning Bacillus anthracis and its potential terrorist misuse. The basic clinical forms are resumed with emphasis on inhalation infection from inspiration of B. anthracis spores. The AVA vaccine licensed in the United States, primary vaccination, protective efficacy of the vaccine, and adverse events are characterised. Stress is laid on pre-exposure and post-exposure prophylaxis of anthrax.